Understanding the molecular alterations that confer metastatic properties, such as increased motility, to otherwise benign breast cells is essential to controlling breast cancer and increasing patient survival. We show for the first time that p38γ MAPK regulates breast cancer cell motility and metastasis, in part by affecting expression of another metastasis-associated protein, RhoC, through a novel mode of regulation: modulation of RhoC ubiquitination. The p38γ-RhoC relationship persists across multiple cell lines and in clinical breast cancer specimens. Using a computational mechanical model based on the finite element method, we further demonstrate that p38γ-mediated cytoskeletal changes are sufficient to control cell motility. The model predicted novel dynamics of leading edge actin protrusions, which were experimentally-verified, and proved to be closely related to cell shape and cytoskeletal morphology. We find that p38γ has important clinical relevance, as high p38γ expression is associated with lower overall survival of breast cancer patients. The data presented here (1) provides a detailed characterization of how p38γ contributes to breast cancer progression, (2) presents a new mechanics-based analysis of cell motility, (3) discovers a leading edge behavior in motile cells to accommodate modified cytoskeletal architecture, (4) identifies a novel mechanism for regulating RhoC expression, and (5) nominates p38γ as an important therapeutic target.
Introduction
Breast cancer (BC) presents as a dysplastic disease of mammary epithelial cells, which can grow uncontrollably for years yet remain confined within mammary ducts or lobules. If diagnosed at this early stage BC responds well to therapeutic intervention (1) . BC becomes much more severe once the cancer cells exit the mammary ducts and metastasize to vital organs. Understanding the molecular alterations that confer metastatic properties to otherwise benign cells is therefore essential to controlling the disease and improving patient survival.
p38 MAPK is a serine/threonine kinase that integrates extracellular stimuli and translates them into cellular responses by phosphorylating a network of downstream effector proteins (2) . The p38 arm of the MAPK pathway is effected by four isoforms: p38 α, β, γ and δ. Despite their sequence similarity and shared upstream kinases, the p38 isoforms can have unrelated, and even antagonistic, roles in development and disease (3) (4) (5) (6) (7) . p38γ (also known as MAPK12, ERK6, or SAPK3) is expressed predominantly in muscle tissue where it promotes myoblast differentiation into myotubes (8) (9) (10) (11) .
p38γ mRNA is overexpressed in several cancers (12, 13) and helps increase Ras-induced cancer invasion (14, 15) . Viewing p38γ function from the developmental perspective led us to hypothesize that p38γ enables mesenchymal-like behavior in BC cells by controlling their motility properties.
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Author Manuscript Published OnlineFirst on August 23, 2011; DOI: 10.1158/0008-5472. CAN-11-1291 Using multiple mechanisms of inhibition we reveal that p38γ is a crucial mediator of BC cell motility and metastasis. Our computational model demonstrates the central role of stress fiber orientation in p38γ-mediated cell motility. Through this in silico experimentation, and subsequent in vitro validation, we discover a novel leading edge behavior in motile BC cells. Mechanistically, p38γ elicits its effects at least in part through RhoC GTPase by affecting RhoC ubiquitination and degradation-a regulatory mechanism never before observed for RhoC.
Clinically, high p38γ expression is associated with the basal-like BC subtype and confers a worse prognosis. This work establishes that p38γ is a metastasisenabling gene responsible for mediating BC cell motility and metastasis, in part by regulating cytoskeletal architecture and modulating RhoC.
Materials and Methods

Cell Lines
Untransfected cell lines were cultured in RPMI 1640 (MDA-MB-231, BT549) or DMEM (Hs578t) supplemented with 10% fetal bovine serum, or DMEM/F12 (MCF-10A) supplemented with 10% horse serum. Selection media for shRNAtransfected MDA-MB-231 cells ("scrambled" or "shp38γ") was standard cell line media containing 1μg/ml puromycin. MDA-MB-231 stably transfected with both shRNA and RhoC/RhoC G14V were cultured in standard cell line media containing 1μg/ml puromycin and 350μg/ml G418. All cell lines were grown at 37°C in a humidified 5% CO 2 incubator. 
Phospho-p38γ Immunoprecipitation/Western Blot
Protein was extracted from 70% confluent cells with RIPA buffer. Total protein extracts were incubated with primary antibody (anti-p38γ or anti-phospho-p38) overnight at 4°C. The following morning protein-antibody complexes were captured by incubation with protein A/G beads (Santa Cruz Biotechnology).
Immunoprecipitates were run on an SDS-PAGE gel, transferred to a nitrocellulose membrane, and probed with the appropriate reciprocal antibody (anti-p38γ or anti-phospho-p38). All immunoprecipitation and western blot data represent at least 3 independent experiments.
In situ detection/quantification of protein expression
Tumors and Patients
Fresh and formalin-fixed, paraffin-embedded tissue blocks of BC were obtained from the files of the Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI. IRB approval was obtained and the diagnosis was confirmed by morphology. After pathological review, a tissue microarray was constructed from the most representative area using the methodology of Nocito et al. (17) . Survival data was obtained from the The University of Michigan's Cancer Registry.
Immunohistochemical Staining and AQUA analysis.
Triple immunofluorescence staining was performed as previously described (18) and the AQUA system (HistoRx, New Haven, Connecticut) was used for 
Statistical analyses
Research. 
Results
p38γ phosphorylation is elevated in an aggressive BC cell line
p38 is activated by dual phosphorylation of the Thr and Tyr residues of the conserved TGY motif (3, 19) . To assess p38γ functional relevance in aggressive BC, we assayed phospho-p38γ levels in a representative and widely used aggressive BC cell line, MDA-MB-231 ("231 cells"). Compared to the nontumorigenic mammary epithelial cell line MCF-10A, 231 cells have increased levels of phosphorylated p38γ, despite similar levels of total p38γ (Fig. 1A) .
To investigate the role of p38γ on the metastatic features of 231 cells we used small hairpin RNA ("shRNA") to stably knock down p38γ expression (Fig. 1B) .
Importantly, the shRNA did not affect expression of the other three p38 isoforms ( Supplementary Fig. S1A ). Since there is no p38γ-specific pharmacologic Fig. S2C ). This change was quantified by the cells' aspect ratio (see Methods). As depicted in Fig. 1C (right), shp38γ cells are significantly less elongated than scrambled cells.
We further asked whether the actin cytoskeleton was modified in shp38γ cells.
Immunofluorescent confocal microscopy revealed that shp38γ cells have a strikingly disorganized actin cytoskeleton (Fig. 1D) , as do DNp38γ cells ( Supplementary Fig. S2E ). Scrambled cells exhibit mesenchymal-like polarization with cell-length stress fibers oriented at 3.42º ± 1.89º (mean ± std. dev.) on either side of the normal to the leading edge (Fig. 1D ). shp38γ cells retain thick actin bundles resembling stress fibers, but primarily confined to the leading edge and with a bimodal orientation distribution at 61.08° ± 3.94º (mean ± std. dev.) ( Elongated cell shape is one factor that delineates both the mode of motility used by a cell and metastatic from non-metastatic cancer cells in vitro (22, 23) . To determine whether the shp38γ cells' rounded shape and modified cytoskeletal architecture indicated a change in metastatic properties we first analyzed cell motility-specifically unstimulated random walk-using time lapse microscopy. p38γ knockdown profoundly affected the quality of cell motility (Fig. 1E , left) and their speed (Fig. 1E , right). Scrambled control cells had a mesenchymal-like motility, consistent with their appearance and cytoskeletal structure, using long pseudopodial projections to "pull" themselves along in alternating cycles of protrusion and contraction (Fig. 1E , top left, and Movie 1). shp38γ cells, however, remained un-polarized and were unable to form long pseudopodia (Fig. 1E , bottom left, and Movie 2). The cells moved inefficiently using broad lamellipodialike structures and exhibited detachment anomalies at the rear of the cell.
Quantitatively, p38γ knockdown significantly reduced cell speed (Fig. 1E , right).
We also investigated p38γ function in cancer cell invasion and aggressive 3D growth and found that p38γ knockdown significantly impaired both properties (Fig. 1D) , and the mechanical properties of actin fibers and cell membranes of mammalian cells (Supplementary Table S1 ) we varied the rates of actin filament protrusion and retraction as model inputs to successfully recreate the observed locomotion of live scrambled cells (Fig. 1F , top, and Movie 3).
To determine whether actin cytoskeletal architecture delineates the motility of the two MDA-MB-231 phenotypes we next created a computational model of shp38γ cells, using the dimensions reported in Supplementary Table S2 and Fig. 1C , the cytoskeletal morphology of actin bundles at ±61.08º ( Fig. 1D and Supplementary   Fig. S3 ) and the same mechanical properties of actin fibers and cell membrane as for the scrambled cells (Supplementary Table S1 ). We further conjectured, and computationally demonstrated, that the observed oscillations in motion of shp38γ cells that are evident in Movie 2 were only possible if the two families of actin bundles at ±61.08º alternate (are out of phase) in their protrusion and retraction (data not shown). When incorporated, these alternating dynamics, albeit not precisely timed, produced a disjoint crawling motion with oscillations of the cell body of the computational shp38γ cell. This motility was remarkably similar to our live shp38γ cell motility (Fig. 1E , bottom, and Movie 3), suggesting that actin cytoskeletal architecture is important for defining shp38γ cell motility.
However, further experiments were necessary to separate the influence of actin fiber orientation from actin protrusion/retraction dynamics. 
scrambled cells (Movie 1). Also note the larger amplitudes of leading edge protrusions in shp38γ cells (Fig. 2C ).
These live cell results confirmed the computational model predictions. We repeated our computational cell motility studies with the mean left/right leading edge protrusion amplitudes and time periods, and trailing edge retraction rates ( Supplementary Fig. S4A ) which we measured via time-lapse microscopy now 
Expression of the cytoskeletal remodeler and metastasis-promoting gene
RhoC is decreased in shp38γ cells
Rho-family GTPases (Rac, Rho, and cdc42) are the classic regulators of actin cytoskeletal dynamics driving cell motility (24) . Based on the actin cytoskeletal changes and motility defects we observed, we hypothesized that p38γ knockdown affected members of the Rho GTPase family. Interestingly, we found that RhoC GTPase protein levels were downregulated in both shp38γ and DNp38γ cells (Fig. 3A and Supplementary Fig. S2F ), with no change in the close homolog RhoA (data not shown). Surprisingly, RhoC mRNA levels were unaffected by p38γ knockdown (Fig. 3B) , suggesting p38γ influences RhoC expression at the translational or post-translational level.
p38γ knockdown leads to increased RhoC ubiquitination and degradation
To determine whether p38γ affects RhoC expression at the translational or posttranslational level we treated scrambled and shp38γ cells with the translation inhibitor cycloheximide and observed the effect on protein expression.
Cycloheximide treatment caused RhoC protein levels to rapidly decrease in shp38γ cells with no corresponding decrease in scrambled cells (Fig. 3C), indicating that RhoC protein is less stable in shp38γ cells.
Upon observing this change in stability we asked whether RhoC was ubiquitinated in shp38γ cells-a common marker of proteins slated for degradation. Upon assaying RhoC ubiquitination we found that levels of ubiquitinated RhoC were increased in shp38γ compared to scrambled cells (Fig.   3D ). To elucidate the RhoC degradation mechanism, we treated cells with either proteasome inhibitors (MG132 or lactacystin) or lysosome inhibitors (ammonium chloride or chloroquine) and observed the effect on RhoC protein levels.
Lysosome inhibition caused an increase in RhoC protein (Fig. 3E) whereas proteasome inhibitors had no effect on RhoC expression (Supplementary Fig.   S1D ), indicating that ubiquitinated RhoC is degraded by the lysosome. Taken together, these data support the conclusion that p38γ affects RhoC expression by mediating RhoC protein stability through regulation of RhoC ubiquitination and lysosomal degradation.
Rescuing RhoC expression restores motility to shp38γ cells
Based on the established roles of RhoC in cell motility and metastasis (25, 26) we hypothesized that decreased RhoC expression in shp38γ cells directly contributes to the impaired motility of shp38γ cells. To test this hypothesis, we stably transfected either RhoC or a constitutively active variant (RhoC G14V) into shp38γ cells and observed the effect on cell motility (Fig. 3F) .
Live cell microscopy revealed that re-expressing RhoC significantly increased motility of the shp38γ cells to levels comparable to scrambled control cells ( 
p38γ affects the metastatic properties of other aggressive BC cell lines
Because p38γ specifically alters the actomyosin contractile motility of MDA-MB-231 cells by affecting RhoC expression, we asked whether it plays a similar role in other mesenchymal-like BC cell lines. To address this question we used two additional widely-studied BC cell lines -Hs578t and BT549 -both of which have increased levels of phosphorylated p38γ compared to both MCF-10A and HME non-tumorigenic mammary epithelial cells (Fig. 4A) . We transiently knocked down p38γ expression in these two cell lines with siRNA ( Fig. 4B ) and observed the effects on the actin cytoskeleton and cell motility. (Figs. 4E-F) . p38γ knockdown in these cell lines also reduced RhoC expression (Fig. 4G) . Taken together, these results support our conclusion that p38γ plays a crucial role in promoting motility of aggressive BC cells by modulating RhoC expression.
p38γ is associated with the basal-like BC subtype
Having discovered that p38γ is associated with mesenchymal-like cell motility and is overactivated in three basal-like BC cell lines, we hypothesized that p38γ is associated with the basal-like BC subtype. To test this hypothesis we assayed p38γ expression in 43 BC patient samples that were previously analyzed for molecular subtype by PAM50 (27) . We divided the cohort into "high" (top 25%) and "low" (bottom 75%) p38γ-expressing tumors and examined the association between p38γ expression level and molecular subtype. We found that the basallike subtype is significantly enriched in the high p38γ-expressing tumors (p = 0.018, Fig. 5A ), whereas none of the other subtypes examined showed significant association with p38γ expression (data not shown). Taken together with our in vitro data, this clinical data strongly supports an association between high p38γ expression and the basal-like BC subtype. the extensive body of in vitro data presented here, strongly suggests that p38γ is necessary for metastasis, and that it exerts its effects, at least in part, by promoting cell motility through regulation of RhoC.
As a final determination of the clinical relevance of p38γ expression we assayed p38γ levels in a cohort of 118 BC cases containing patient survival data. Using the same high/low cutoffs as the molecular subtype analysis, we found a significant association between high p38γ expression and lower overall patient survival (p = 0.013, Fig. 5D ). This clinical data supports our in vitro and in vivo findings that p38γ is an important mediator of BC cell aggressiveness, establishing that p38γ expression has important implications for BC patient outcome.
Discussion
As the breast is a non-vital organ, primary tumor burden is very rarely the direct cause of cancer-specific mortality. Instead, metastasis of cells from the primary tumor to vital organs results in patient death. Here we demonstrate that p38γ is a novel metastasis-associated gene, which acts in part by affecting cytoskeletal orientation, cell motility, and RhoC.
The importance of the p38 MAPK pathway in cancer has been appreciated (6, 28) , but diverse, and sometimes contradictory, roles have been described for p38 in cancer (13) . In agreement with other recent findings (15, 29) we show that at least some of the discrepancy in p38 function may be attributed to the distinct contributions of p38 isoforms. The p38 MAPK pathway is ubiquitously utilized in stress-response., It logically follows that metastasizing cancer cells, which encounter an ever-changing milieu of cellular stresses, may gain survival advantages under stressed conditions upon modulation of the appropriate p38 MAPK isoforms; thus, dissecting the contributions of each p38 isoform would allow more precise targeting of specific subsets of cancer. p38γ is an especially promising drug target as, in addition to the data presented here, it is a kinase, has restricted tissue expression (8, 10, 11) , and lacks a phenotype when 
Using a computational cell model in combination with live cell microscopy studies we showed that p38γ promotes BC cell motility at least in part by mediating actin cytoskeletal remodeling to create proper stress fiber orientation. Using the computational cell models, we first noted that whereas the observed whole cell locomotion could be produced by simultaneous action of all stress fibers in scrambled cells, the experimentally-observed ineffective locomotion of shp38γ cells was only possible if the action alternated between the two families of actin bundles seen in this cell phenotype-a result that would prove difficult to demonstrate using cell biological techniques alone.
The computational model predicted, and subsequent biological experiments verified, the presence of left-right leading edge protrusion oscillations in both scrambled and shp38γ cells. We note that other groups have identified oscillations in components of the leading edge (31, 32) , however these oscillations all involved forward-backward (protrusion-retraction) movement of the leading edge as a whole. To the best of our knowledge the data presented here is thus the first evidence of left-right oscillations in the leading edge. Interestingly, the principle difference between the two cell types studied here (scrambled and shp38γ) lies in the periodicity of these oscillations. Through detailed in silico experimentation (Fig. 2, Supplementary Fig. S4 ) we determined that leading edge protrusion oscillation periodicity is influenced by and inseparable from morphology. While this is a subject for future investigation, we do speculate on the chain of events: p38γ knockdown results in cytoskeletal architecture changes, which lead to alteration of cell shape, compensatory changes in leading edge protrusion periodicity, and ultimately modified whole cell motility.
Oscillation of other components of cell motility, such as cell shape (33) and trailing edge retraction (34) , have been shown to be essential for productive cell motion in Dictyostelium (33) and fish keratocytes (34) . We expect further investigations to uncover links between these processes and leading edge protrusion oscillations. RhoC is involved in stress fiber formation and actomyosin contraction (38, 39)-both of which are perturbed by p38γ knockdown-and has previously been linked to the p38 MAPK pathway (40). RhoC also drives metastasis in several types of cancer, including breast (38, (41) (42) (43) , and plays a larger role in stress fiber formation and contraction than RhoA (44); thus we postulated that changes in RhoC expression influence the shp38γ phenotype. Supporting this hypothesis we found that re-expressing RhoC alone was sufficient to restore motility to shp38γ cells-a surprising feat, given the multitude of proteins involved in cell motility (45, 46) , which highlights the importance of RhoC in p38γ-mediated cell motility.
Further supporting the p38γ-RhoC link is our finding that expression of the two proteins is concurrently altered in clinical BC specimens (Fig. 5A) , suggesting that the p38γ-RhoC axis may be functionally significant-and a potentially druggable target-in the clinic.
We discovered that p38γ regulates RhoC expression by preventing RhoC ubiquitination and subsequent lysosomal degradation. Although other p38 isoforms have been linked to protein ubiquitination (47, 48) , ours is the first evidence of p38γ contributing to this process. Ubiquitination and protein degradation have recently emerged as important mechanisms for regulating Rho GTPase expression (49) , however this is the first demonstration of modulating 
